Skip to Main Content

Paper Details

Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia.
Blood Adv
4
2023
Author NameAffiliation
Farhad RavandiThe University of Texas MD Anderson Cancer Center
Hagop KantarjianThe University of Texas MD Anderson Cancer Center
  • 1 - 2

Datasets

Release 1.2